TECODEVELOPMENT GMBH

Their core work

TecoDevelopment is a German SME specializing in preclinical drug safety testing, with particular focus on immunoassay development and complement system pathology diagnostics. They develop in vitro testing methods that help pharmaceutical companies assess drug-related immune responses before clinical trials. Their work spans from personalized cancer vaccine formulation screening to biosafety assays for predicting adverse complement reactions to therapeutics.

What they specialise in

How they've shifted over time

TecoDevelopment entered H2020 in 2019 with work on personalized cancer vaccine formulation (Need2immune), then quickly focused on drug safety diagnostics through immunoassay development and biosafety testing in 2020. Their trajectory shows a narrowing from broader biomedical formulation work toward a specialized niche in complement-related drug safety assessment. With only a two-year window of activity (2019–2020 start dates), the evolution is early-stage but directionally clear.

Moving toward specialized preclinical diagnostic tools for predicting immune-mediated adverse drug reactions, particularly complement pathway activation.

How they like to work

TecoDevelopment prefers to lead — they coordinated 2 of their 3 projects, suggesting confidence in driving research agendas despite being a small company. Their consortia are compact (5 unique partners across 4 countries), indicating they work in focused, small-team settings rather than large multi-partner frameworks. This is typical for MSCA-funded industry hosts who bring specific technical capability rather than broad network reach.

A small but internationally distributed network of 5 partners across 4 countries, built through MSCA fellowships and a CSA project. Their partnerships appear project-specific rather than reflecting a deep recurring network.

What sets them apart

TecoDevelopment occupies a specific niche at the intersection of immunoassay development and drug safety prediction — particularly around complement system reactions, an area underserved by larger CROs. As an SME that coordinates its own MSCA projects, they demonstrate both scientific depth and project management capability. For pharma companies or academic groups needing a specialized preclinical testing partner for immune-mediated drug reactions, they offer focused expertise without the overhead of a large contract research organization.

Highlights from their portfolio

• immunoassays
  Core to their identity — coordinated project developing new diagnostic tools for drug-related complement pathology, their clearest area of specialization.
• Need2immune
  Demonstrates breadth beyond diagnostics into therapeutic formulation, coordinating work on rapid screening for personalized cancer vaccines.
• Biosafety
  Their only participant role, linking them to the wider biosafety and in vitro testing community through a Widening Participation CSA project.